World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
122
Citations
93764
World Ranking
3395
National Ranking
1868

Overview

Lon S. Schneider is affiliated with the University of Southern California in the United States. Their research primarily focuses on medicine, with significant contributions in physiology, psychiatry and mental health, molecular biology, cognitive neuroscience, and neurology.

The scientist has published extensively on topics including Alzheimer's disease research and treatments, dementia and cognitive impairment research, functional brain connectivity studies, cholinesterase and neurodegenerative diseases, prion diseases and protein misfolding, diet and metabolism studies, and neuroinflammation and neurodegeneration mechanisms.

Recent papers authored or co-authored by Lon S. Schneider include the following:

  • APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline, 2020, Nature
  • Spread of pathological tau proteins through communicating neurons in human Alzheimer's disease, 2020, Nature Communications
  • The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease, 2020, Alzheimer's Research & Therapy
  • In vivo staging of regional amyloid deposition, 2022, Columbia Academic Commons (Columbia University)
  • Alzheimer Disease as a Clinical-Biological Construct-An International Working Group Recommendation, 2024, JAMA Neurology

Frequent co-authors collaborating with Schneider include John C. Morris, Arthur W. Toga, Michael Donohue, Paul Aisen, and William J. Jagust.

The scientist frequently publishes in several venues, with multiple contributions to:

  • Nature Communications
  • The Journal of Prevention of Alzheimer's Disease
  • Alzheimer's & Dementia
  • Alzheimer's Research & Therapy
  • Alzheimer's & Dementia Diagnosis Assessment & Disease Monitoring

Best Publications

  • Dementia prevention, intervention, and care: 2020 report of the Lancet Commission.

    Gill Livingston;Gill Livingston;Jonathan Huntley;Andrew Sommerlad;Andrew Sommerlad;David Ames

  • Dementia prevention, intervention, and care

    Gill Livingston;Gill Livingston;Andrew Sommerlad;Vasiliki Orgeta;Sergi G Costafreda;Sergi G Costafreda

  • Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

    Bruno Dubois;Bruno Dubois;Howard H Feldman;Claudia Jacova;Harald Hampel;Harald Hampel

  • A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study

    Mary Sano;Christopher Ernesto;Ronald G. Thomas;Melville R. Klauber

  • Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease.

    Adam C. Naj;Gyungah Jun;Gary W. Beecham;Li-San Wang

  • Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.

    Lon S. Schneider;Karen S. Dagerman;Philip Insel

  • Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.

    Bruno Dubois;Harald Hampel;Harald Hampel;Howard H. Feldman;Philip Scheltens

  • Analysis of shared heritability in common disorders of the brain

    Verneri Anttila;Verneri Anttila;Brendan Bulik-Sullivan;Brendan Bulik-Sullivan;Hilary K. Finucane;Raymond K. Walters;Raymond K. Walters

  • Defeating Alzheimer's disease and other dementias: a priority for European science and society

    Bengt Winblad;Bengt Winblad;Philippe Amouyel;Sandrine Andrieu;Clive Ballard

  • Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction.

    Daniel A Nation;Melanie D Sweeney;Axel Montagne;Abhay P Sagare

  • Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.

    Lon S. Schneider;Pierre N. Tariot;Karen S. Dagerman;Sonia M. Davis

  • Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society.

    Gary W. Small;Peter V. Rabins;Patricia P. Barry;Neil S. Buckholtz

  • A 30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients With Alzheimer's Disease

    Margaret J. Knapp;David S. Knopman;Paul R. Solomon;William W. Pendlebury

  • Diagnosis and Treatment of Depression in Late Life: Consensus Statement Update

    Barry D. Lebowitz;Jane L. Pearson;Lon S. Schneider;Charles F. Reynolds

  • Memantine for dementia

    Rupert McShane;Maggie J Westby;Emmert Roberts;Neda Minakaran

  • Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis

    Y. Iturria-Medina;R. C. Sotero;P. J. Toussaint;J. M. Mateos-Pérez

  • APOE4 leads to blood–brain barrier dysfunction predicting cognitive decline

    Axel Montagne;Daniel A. Nation;Abhay P. Sagare;Giuseppe Barisano

  • Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease

    Rebecca Sims;Sven J. Van Der Lee;Adam C. Naj;Céline Bellenguez;Céline Bellenguez

  • Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials.

    Lon S. Schneider;Karen Dagerman;Philip S. Insel

  • A Metaanalysis of Controlled Trials of Neuroleptic Treatment in Dementia

    Lon S. Schneider;Vicki E. Pollock;Scott A. Lyness

Frequent Co-Authors

Paul S. Aisen
Paul S. Aisen University of Southern California
Pierre N. Tariot
Pierre N. Tariot University of Rochester
Mary Sano
Mary Sano Icahn School of Medicine at Mount Sinai
Constantine G. Lyketsos
Constantine G. Lyketsos Johns Hopkins University
John C. Morris
John C. Morris Washington University in St. Louis
Ronald G. Thomas
Ronald G. Thomas University of California, San Diego
Gary Cutter
Gary Cutter University of Alabama at Birmingham
Helena C. Chui
Helena C. Chui University of Southern California
Rachelle S. Doody
Rachelle S. Doody Roche (Switzerland)
Daniel Weintraub
Daniel Weintraub University of Pennsylvania

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in medical careers beyond traditional MD programs, several affordable online nursing degrees offer flexible options. A key question for aspiring nurses is what is the cheapest online college for nursing? Affordable online programs help lower the barrier to entry, making nursing degrees more accessible.

Many registered nurses (RNs) seek career advancement through a Bachelor of Science in Nursing. Finding the rn to bsn cheapest program can reduce costs and speed up completion times for working professionals. Similarly, non-nurses interested in leadership or specialized roles can consider online MSN pathways, including the direct entry msn online for those with non-nursing bachelor's degrees.

For those interested in academic or high-level clinical positions, earning a doctorate is often essential. Accredited online phd nursing programs provide advanced education while accommodating busy schedules.

Exploring these online pathways can help shape a rewarding healthcare career—whether starting in nursing or seeking the highest credentials in the field.

Best Scientists Citing Lon S. Schneider

Trending Scientists